The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 23, 2017

Filed:

Sep. 26, 2013
Applicants:

Institut Pasteur, Paris, FR;

Themis Bioscience Gmbh, Vienna, AT;

Centre National DE LA Recherche Scientifique, Paris, FR;

Inventors:

Frederic Tangy, Les Lilas, FR;

Samantha Brandler, Bouguenais, FR;

Philippe Despres, Sant-Denis La Reunion, FR;

Andre Habel, Hamburg, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/02 (2006.01); A61K 39/12 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); A61K 39/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/12 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/70 (2013.01); C12N 2760/18421 (2013.01); C12N 2760/18434 (2013.01); C12N 2760/18443 (2013.01); C12N 2760/18444 (2013.01); C12N 2770/36122 (2013.01); C12N 2770/36123 (2013.01); C12N 2770/36134 (2013.01);
Abstract

The invention relates to recombinant Measles virus expressing Chikungunya virus polypeptides, and concerns in particular virus like particles (VLP) that contain envelope and capsid proteins of a Chikungunya virus at their surface. These particles are recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acids, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by Chikungunya virus.


Find Patent Forward Citations

Loading…